GlaxoSmithKline Laval facility becomes North America vaccine research and development headquarters
$50 million investment to support new role
15-Jun-2007
Scientists in Laval will focus research and development work in the areas of adjuvant technologies, molecular biology, immunology, respiratory viral vaccines, allergy, oncology and process development.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.